CN110787293A - Antibacterial cleaning composition for wound and wound plaster - Google Patents
Antibacterial cleaning composition for wound and wound plaster Download PDFInfo
- Publication number
- CN110787293A CN110787293A CN201810880264.9A CN201810880264A CN110787293A CN 110787293 A CN110787293 A CN 110787293A CN 201810880264 A CN201810880264 A CN 201810880264A CN 110787293 A CN110787293 A CN 110787293A
- Authority
- CN
- China
- Prior art keywords
- wound
- antibacterial
- cleaning composition
- composite
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 67
- 238000004140 cleaning Methods 0.000 title claims abstract description 45
- 239000011505 plaster Substances 0.000 title abstract description 19
- 206010052428 Wound Diseases 0.000 claims abstract description 112
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 112
- 239000002131 composite material Substances 0.000 claims abstract description 36
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 25
- 241000588626 Acinetobacter baumannii Species 0.000 claims abstract description 19
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 230000002949 hemolytic effect Effects 0.000 claims abstract description 18
- 241000222122 Candida albicans Species 0.000 claims abstract description 17
- 241000588724 Escherichia coli Species 0.000 claims abstract description 17
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 17
- 241000194017 Streptococcus Species 0.000 claims abstract description 17
- 229940095731 candida albicans Drugs 0.000 claims abstract description 17
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 16
- 235000013601 eggs Nutrition 0.000 claims abstract description 16
- 241000287828 Gallus gallus Species 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 22
- 229920001661 Chitosan Polymers 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 102000015636 Oligopeptides Human genes 0.000 claims description 14
- 108010038807 Oligopeptides Proteins 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 235000008434 ginseng Nutrition 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- 239000002390 adhesive tape Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000020 Nitrocellulose Substances 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 229920001220 nitrocellulos Polymers 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 abstract description 12
- 230000029663 wound healing Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 206010048038 Wound infection Diseases 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 19
- 244000052616 bacterial pathogen Species 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000000853 adhesive Substances 0.000 description 11
- 230000001070 adhesive effect Effects 0.000 description 11
- 230000035876 healing Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 208000003322 Coinfection Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- 235000010520 Canavalia ensiformis Nutrition 0.000 description 1
- 235000010518 Canavalia gladiata Nutrition 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 231100000458 skin sensitization testing Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to an antibacterial cleaning composition for wounds and a wound plaster, and relates to the field of medicines. The active ingredients of the antibacterial cleaning composition comprise a composite yolk antibody, and the composite yolk antibody is prepared by the following method that inactivated staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa, cluster A B type hemolytic streptococcus and candida albicans are mixed to obtain a strain mixture, the strain mixture is dissolved to prepare a composite antigen, the composite antigen is injected on a chicken body to perform immune enhancement, eggs laid by the chicken after immune enhancement are collected, and then the eggs are separated and purified. The wound plaster containing the antibacterial cleaning composition has the advantages of effectively sterilizing and cleaning wounds, preventing wound infection and promoting wound healing.
Description
Technical Field
The invention relates to the field of medicines, and in particular relates to an antibacterial cleaning composition for wounds and a wound plaster.
Background
Wound repair is a complex process involving multiple cells and multiple cytokines, the wound dressing is very important in treating or repairing wounds, when the dressing is used for treating the wounds, the dressing is mainly used for disinfecting and sterilizing the wounds to avoid further infection of the wounds, then the self healing and repairing capability of the body is utilized to wait for the wounds to heal, and finished wound repair dressings on the market at present are provided with patches or powder, and are extremely inconvenient for treating large-area, irregular or difficultly treated wounds.
The woundplast is one of the most common surgical medicines in human life. The band-aid, also called as hemostatic plaster, has the functions of hemostasis and wound protection. It is made up by using a long adhesive tape and a small piece of yarn soaked with medicine through the middle portion of said adhesive tape. Due to the structural limitation of the band-aid, the band-aid can only be used for emergency treatment of small wounds, thereby playing the roles of temporary hemostasis and wound surface protection. It should be noted, however, that the time of use is not necessarily too long. If it is used for a long time, the adhesive plaster on the outer layer of the band-aid is not breathable. The wound and the skin surrounding the wound are whitened and become soft leading to a secondary infection with pathogenic bacteria, which further worsens the wound. Therefore, it is desirable to provide a composition and a wound dressing that can solve the above problems and have a specific bactericidal effect.
Disclosure of Invention
The invention aims to provide an antibacterial cleaning composition for wounds, which can effectively resist staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa, cluster A B type hemolytic streptococcus and candida albicans, has a simple preparation method, effectively enables all antibodies to exist simultaneously, is synergistic with each other, has good activity and good specific sterilization effect, and does not influence the micro-ecological balance.
Another object of the present invention is to provide a wound dressing which can effectively sterilize a wound, prevent wound infection, and promote wound healing.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
The invention provides an antibacterial cleaning composition for wounds, which is characterized in that the active ingredients of the antibacterial cleaning composition comprise a composite yolk antibody, and the composite yolk antibody is prepared by the following method:
mixing inactivated staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa, A cluster B type hemolytic streptococcus and candida albicans to obtain a strain mixture, dissolving the strain mixture to obtain a composite antigen, injecting the composite antigen onto a chicken body for immune enhancement, collecting eggs laid by the chicken with enhanced immunity, and separating and purifying the eggs.
The invention provides a wound plaster which contains the antibacterial cleaning composition.
The antibacterial cleaning composition for the wound and the wound plaster provided by the embodiment of the invention have the beneficial effects that:
the inventor finds that staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, A cluster type B hemolytic streptococcus and candida albicans exist in most of inflammation or infection of wounds, and acinetobacter baumannii is an important pathogenic bacterium of hospital infection, so certain acinetobacter baumannii also exists in inflammation or infection of wounds. In recent years, the infection is increased, and the drug resistance is increasingly serious. The active component of the antibacterial cleaning composition for the wound comprises the composite yolk antibody, and the composite yolk antibody can be specifically combined with corresponding antigens, so that the 6 pathogenic bacteria can be safely and effectively killed, the dosage of antibiotics can be reduced, the pathogenic bacteria can be resistant to drugs, the 6 pathogenic bacteria can be killed, secondary infection can be prevented and treated, the pain of a patient can be reduced, and the wound healing can be promoted.
The wound plaster containing the antibacterial cleaning composition has the advantages of effectively sterilizing wounds, preventing wound infection and promoting wound healing.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The following provides a detailed description of the antibacterial cleansing composition for wounds and the wound dressing according to the embodiments of the present invention.
The inventors found that staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, cluster a B type hemolytic streptococcus, and candida albicans are mostly present in inflammation or infection due to a wound. Meanwhile, acinetobacter baumannii is an important pathogenic bacterium of hospital infection, so certain acinetobacter baumannii exists in inflammation or infection of wounds. In recent years, the infection is increased, and the drug resistance is increasingly serious. In order to reduce the dosage of antibiotics and the drug resistance of each pathogenic bacterium, and simultaneously kill the 6 pathogenic bacteria, prevent and treat secondary infection, reduce the pain of patients and promote the healing of wounds, the invention provides the antibacterial cleaning composition for the wounds, and the active component of the antibacterial cleaning composition comprises a composite egg yolk antibody which can be specifically combined with corresponding antigens, so that the 6 pathogenic bacteria can be killed safely and effectively, and the healing of the wounds can be promoted.
Specifically, the composite yolk antibody is prepared by the following method:
mixing inactivated staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa, A cluster B type hemolytic streptococcus and candida albicans to obtain a strain mixture, dissolving the strain mixture to obtain a composite antigen, injecting the composite antigen onto a chicken body for immune enhancement, collecting eggs laid by the chicken with enhanced immunity, and separating and purifying the eggs. It can effectively inhibit or kill Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, A cluster B type hemolytic streptococcus and Candida albicans.
In a preferred embodiment of the invention, the strain mixture comprises, by mass, 14% -20% of staphylococcus aureus, 10% -15% of escherichia coli, 10% -20% of acinetobacter baumannii, 9% -15% of pseudomonas aeruginosa, 25% -40% of cluster A B type hemolytic streptococcus and 10% -15% of candida albicans.
Preferably, the strain mixture comprises, by mass, 15% -17% of staphylococcus aureus, 10% -13% of escherichia coli, 13% -17% of acinetobacter baumannii, 10% -12% of pseudomonas aeruginosa, 30% -40% of cluster A B type hemolytic streptococcus and 10% -11% of candida albicans. Under the conditions of the above proportions, the sterilizing effect is good.
Preferably, in a preferred embodiment of the present invention, the step of preparing the composite antigen after dissolving the mixture of strains comprises:
and mixing the dissolved strain mixture with a Freund adjuvant according to the mass ratio of 1:1-1.3, and homogenizing, wherein the concentration of the strain mixture is 0.8-2.5 mg/ml. The dissolution may be performed using a reagent such as PBS.
Preferably, in a preferred embodiment of the present invention, the egg is separated and purified, mainly from the yolk of the egg.
In a preferred embodiment of the present invention, in order to further improve the antibacterial ability of the antibacterial cleansing composition, prevent secondary infection, promote wound healing, and improve comfort, the active ingredients preferably further comprise guanidinated chitosan, dimethyl sulfoxide, ginseng oligopeptide, and vitamin E.
Preferably, the mass ratio of the composite yolk antibody, the guanidinated chitosan, the dimethyl sulfoxide, the ginseng oligopeptide and the vitamin E is 1.3-2.5:0.3-0.5:0.3-0.5:1-2:0.05-0.1 in sequence. Wherein, the guanylated chitosan is matched with vitamin E and ginseng oligopeptide to effectively promote the healing of wounds.
Chitosan is a biological material with good hemostatic, antibacterial and adsorption capacities, and the antibacterial property and the adsorption performance of chitosan can be improved by introducing a guanidino group at an amino group of chitosan, so that chitosan is a common material for chemical separation. The guanidinated chitosan shortens the whole blood coagulation time and has certain hemostatic ability; in vitro coagulation index results show that guanidinated chitosan does not act through the traditional endogenous and exogenous coagulation pathways, and no exact research at present proves that a guanidino group can promote coagulation, so that the effect is possibly dependent on chitosan; MTT detection results show that the cell proliferation rate of the guanidino chitosan is 87.8%, and the toxic reaction is grade 1; the fluorescent staining pictures show that the number of living cells is large and the number of dead cells is small, which indicates that the toxicity of the guanidine chitosan to the cells is low. Therefore, the introduction of the guanidinylated chitosan can effectively promote the healing of the wound.
Dimethyl sulfoxide can be mutually soluble with a plurality of organic solvents and water, and simultaneously, the dimethyl sulfoxide has the special property of being easy to permeate into the skin, is beneficial to the permeation of the medicine into the human body, so that the effective components can rapidly permeate into the skin of the human body, and simultaneously, the dimethyl sulfoxide has the functions of diminishing inflammation, relieving pain, calming, promoting wound healing and the like, so that the medicine effect of the antibacterial cleaning composition can be further improved, and the dimethyl sulfoxide can also effectively improve the stability of the antibacterial cleaning composition in a cold environment.
The marine small molecular oligopeptide can obviously improve the proliferation capacity of spleen and lymph cells of mice induced by the sword bean protein A (ConA), the number of hemolytic plaques of antibody-producing cells, the content of serum hemolysin and the activity of natural killer cells (NK cells). It can be seen that the oligopeptide can play a better role in the aspects of cellular immunity, humoral immunity and NK cell activity enhancement. Through the immunoregulation effect of the ginseng oligopeptides on mice, the ginseng oligopeptides are found to have good immunoregulation function and have the potential of being a novel immunity-enhancing preparation.
Vitamin E can protect T lymphocyte, protect erythrocyte, resist free radical oxidation, inhibit platelet aggregation to reduce risk of myocardial infarction and cerebral infarction, and has good therapeutic effect on burn, cold injury, capillary hemorrhage, climacteric syndrome, and skin care.
The guanidinated chitosan, the vitamin E, the ginseng oligopeptide and the composite yolk antibody cooperate to promote the sterilization effect of the composite yolk antibody on the 6 pathogenic bacteria.
Based on the antibacterial cleaning composition, the invention also provides a wound plaster which contains the antibacterial cleaning composition.
When the adhesive bandage is a solid adhesive bandage, the adhesive bandage further comprises an adhesive tape strip, a cushion layer and isolation paper, the cushion layer is loaded with the antibacterial cleaning composition, and the adhesive tape strip is provided with air holes, so that the wound and skin around the wound are effectively prevented from whitening and softening to cause secondary infection of pathogenic bacteria while sterilization is effectively achieved.
When the wound plaster is a liquid wound plaster, the wound plaster also comprises a carrier, the antibacterial cleaning composition and the carrier are fully mixed to form a colloidal solution, and the mass ratio of the antibacterial cleaning composition to the carrier is 1-10: 75-90. It can be applied to the wound by coating or spraying while forming a conjunctiva. Meanwhile, the liquid wound plaster can ensure the sealing property of the wound surface and provide a moist environment for the wound surface, thereby being more beneficial to the healing of the wound.
In a preferred embodiment of the invention, the carrier comprises, by weight, 2-3 parts of cellulose nitrate, 1-2 parts of polyvinylpyrrolidone, 1-2 parts of glycerol, 3-5 parts of ethanol, 3-5 parts of sodium alginate and 80-90 parts of deionized water. The liquid adhesive bandage is characterized in that the liquid adhesive bandage is made of cellulose nitrate, and the cellulose nitrate is a film forming material, can form a film quickly, ensures the sealing property of a wound surface, has certain hydrophilicity, ensures the wettability of the wound surface, promotes wound healing, has certain breathing aperture capable of ensuring the wound surface, prevents external pathogenic bacteria from infecting, and is more attractive compared with a solid adhesive bandage. The polyvinylpyrrolidone has good adhesion, promotes film formation, keeps the glycerol moisture, and keeps the stability of the sodium alginate. Under the conditions, the antibacterial and anti-infection effects of the antibacterial cleaning composition for the wounds are better.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
An antibacterial cleansing composition for wounds comprises an active ingredient of a composite yolk antibody, wherein the composite yolk antibody is prepared by the following method:
mixing 15% of staphylococcus aureus, 10% of escherichia coli, 15% of acinetobacter baumannii, 10% of pseudomonas aeruginosa, 40% of cluster A B type hemolytic streptococcus and 10% of candida albicans according to the mass percentage of the 6 inactivated pathogenic bacteria to obtain a strain mixture, dissolving the strain mixture, mixing the dissolved strain mixture and a Freund's adjuvant according to the mass ratio of 1:1, and homogenizing to obtain the composite antigen, wherein the concentration of the strain mixture is 2.5 mg/ml.
Injecting the composite antigen onto chicken body for immunity enhancement, collecting eggs laid by the enhanced chicken, separating and purifying from the eggs.
Example 2
The active ingredients of the antibacterial cleaning composition for the wound comprise a composite yolk antibody, guanidinated chitosan, dimethyl sulfoxide, ginseng oligopeptide and vitamin E, wherein the mass ratio of the composite yolk antibody to the guanidinated chitosan to the dimethyl sulfoxide to the ginseng oligopeptide to the vitamin E is 2:0.4:0.5:1.5: 0.07.
The method for extracting the complex yolk antibody was the same as that provided in example 1.
Example 3
An antibacterial cleansing composition for wounds comprises an active ingredient of a composite yolk antibody, wherein the composite yolk antibody is prepared by the following method:
mixing 16% of staphylococcus aureus, 14% of escherichia coli, 15% of acinetobacter baumannii, 15% of pseudomonas aeruginosa, 30% of cluster A B type hemolytic streptococcus and 10% of candida albicans according to the mass percentage of the 6 inactivated pathogenic bacteria to obtain a strain mixture, dissolving the strain mixture, mixing the dissolved strain mixture and a Freund adjuvant according to the mass ratio of 1:1.3, and homogenizing to obtain the composite antigen, wherein the concentration of the strain mixture is 2 mg/ml.
Injecting the composite antigen onto chicken body for immunity enhancement, collecting eggs laid by the enhanced chicken, separating and purifying from the eggs.
Example 4
The active ingredients of the antibacterial cleaning composition for the wound comprise a composite yolk antibody, guanidinated chitosan, dimethyl sulfoxide, ginseng oligopeptide and vitamin E, wherein the mass ratio of the composite yolk antibody to the guanidinated chitosan to the dimethyl sulfoxide to the ginseng oligopeptide to the vitamin E is 2:0.35:0.5:1:0.08 in sequence.
The compound yolk antibody is prepared by the following method:
mixing 16% of staphylococcus aureus, 12% of escherichia coli, 14% of acinetobacter baumannii, 11% of pseudomonas aeruginosa, 32% of cluster A B type hemolytic streptococcus and 15% of candida albicans according to the mass percentage of the 6 inactivated pathogenic bacteria to obtain a strain mixture, dissolving the strain mixture, mixing the dissolved strain mixture and a Freund's adjuvant according to the mass ratio of 1:1.2, and homogenizing to obtain the composite antigen, wherein the concentration of the strain mixture is 1.4 mg/ml.
Injecting the composite antigen onto chicken body for immunity enhancement, collecting eggs laid by the enhanced chicken, separating and purifying from the eggs.
Example 5
A solid adhesive bandage comprises an adhesive tape, a cushion layer and isolation paper, wherein the cushion layer is loaded with the antibacterial cleaning composition provided by the embodiment 1, and the adhesive tape is provided with air holes.
The method for loading the antibacterial cleaning composition on the cushion layer comprises mixing the antibacterial cleaning composition with water, soaking the cushion layer in the water solution of the antibacterial cleaning composition, and drying.
Example 6
A solid adhesive bandage, which further comprises an adhesive tape, a cushion layer and a piece of isolation paper, wherein the cushion layer is loaded with the antibacterial cleaning composition provided by the embodiment 2, and the adhesive tape is provided with air holes.
Example 7
A liquid wound covering, which comprises a carrier and the antibacterial cleaning composition provided in example 1, wherein the antibacterial cleaning composition and the carrier are fully mixed to form a colloidal solution, and the mass ratio of the antibacterial cleaning composition to the carrier is 1: 90.
The carrier comprises, by weight, 3 parts of cellulose nitrate, 1.3 parts of polyvinylpyrrolidone, 1 part of glycerol, 5 parts of ethanol, 4 parts of sodium alginate and 83 parts of deionized water.
Example 8
A liquid wound covering comprising a carrier and the antibacterial cleansing composition provided in example 3, wherein the antibacterial cleansing composition and the carrier are fully mixed to form a colloidal solution, and the mass ratio of the antibacterial cleansing composition to the carrier is 1: 86.
The vector was the same as that provided in example 7.
Example 9
A liquid wound covering comprising a carrier and the antibacterial cleansing composition provided in example 2, wherein the antibacterial cleansing composition and the carrier are mixed thoroughly to form a colloidal solution, and the mass ratio of the antibacterial cleansing composition to the carrier is 2: 89.
The carrier comprises, by weight, 2.6 parts of cellulose nitrate, 1.5 parts of polyvinylpyrrolidone, 1.3 parts of glycerol, 5 parts of ethanol, 5 parts of sodium alginate and 90 parts of deionized water.
Test examples
Irritation studies were performed with reference to GBT16886.10-2017 medical device biological evaluation part 10-relevant provisions for stimulation and skin sensitization testing.
① skin irritation test
100 volunteers were selected and equally divided into 5 groups of 20 individuals each as test group 1, test group 2, test group 3, test group 4 and test group 5. The band-aid prepared in example 5 was attached to the arm of the volunteer of test group 1, the band-aid prepared in example 6 was attached to the arm of the volunteer of test group 2, the band-aid prepared in example 7 was applied to the arm of the volunteer of test group 3, the band-aid prepared in example 8 was applied to the arm of the volunteer of test group 4, the band-aid prepared in example 9 was applied to the arm of the volunteer of test group 5, and after 24 hours, the occurrence of redness and swelling and other abnormal phenomena was observed, and the band-aid was qualified as specified if no less than 18 persons were present in each group of 20 persons.
After the experiment is finished, the test groups 1 to 5 are all qualified, and have no irritation to the skin.
② test for curative effect:
selecting 5 healthy rabbits with the weight of about 1.5kg, shearing off the hair of the left back leg of each rabbit by using a sterilized operating scissors, removing the residual hair by using a depilator, cleaning the hairs by using warm water, raising the rabbits in a dry and clean environment for 24 hours, and cutting 5 wounds a, b, c, d and e with the same size on the left leg of the rabbit by using a sterilized knife, wherein the wound a is attached with a Yunnan white drug bandage, the wound b is attached with a solid bandage prepared in the embodiment 5 of the invention, the wound c is coated with the liquid bandage provided in the embodiment 7 of the invention, the wound d is coated with the liquid bandage provided in the embodiment 9 of the invention, and the wound e is not treated. After 4h of treatment, the test article was removed and the residual material was rinsed with warm water.
The skin reaction scoring system scores of section 10 were evaluated according to GBT16886.10-2017 medical device biology. The result shows that the solid adhesive bandage and the liquid adhesive bandage provided by the invention slightly stimulate rabbits, and meet the requirements of wound dressing.
Specifically, after 0h of removing the test article, no erythema or edema appeared in the wounds a-d, and after 4h of removing the drug, very slight edema appeared in the wounds a-d, wherein the degree of edema in the wound b was stronger than that in the other wounds a, c and d.
Wound healing was also observed and the results are shown in table 1.
TABLE 1 healing time
From table 1, it is found that wounds a-d all healed shorter than wound e, while wounds c, d healed shorter than wound b.
Meanwhile, colonies containing 6 pathogenic bacteria including 1861x10 are selected3Staphylococcus aureus of cfu, 1521x103cfu E.coli 1723x103cfu Acinetobacter baumannii, 2578x103cfu Pseudomonas aeruginosa, 1159x103cfuA cluster B type hemolytic streptococcus and 912x103The sterilization effect test of the cfu candida albicans is carried out by adopting the antibacterial cleaning composition for the wounds prepared in the examples 1-4, the number of the viable bacteria colony is counted, the counting is repeated for three times, and when the sterilization rate is more than or equal to 90 percent, the product has the sterilization effect.
According to the statistical formula, X is equal to (A-B)/Ax is 100 percent, wherein X is the sterilization rate, A is the average colony number of a control sample, and B is the average colony number of a tested sample. At the end of the experiment, the antibacterial cleansing compositions for wounds provided in examples 1 to 4 all had significant bactericidal effects against the above 6 pathogenic bacteria.
In clinical tests, 30 patients are selected and divided into three groups, wherein the first group is pasted with the solid wound plaster provided by the invention at the wound, the second group is pasted with the liquid wound plaster provided by the invention at the wound, and the third group is coated with the antibacterial cleaning composition provided by the invention at the wound. Tests have shown that three groups can promote wound healing without infection, while the first and second groups have better efficacy than the third group and a shorter healing time, and at the same time, it was found that the antibacterial cleansing composition provided in example 2 has better efficacy than that of example 1, and 5 typical cases are listed below:
1. wangzhi, female, 33 years old. When cooking, the fingers were carelessly scratched, and after the wound was cleaned, the solid wound patch containing the antibacterial cleansing composition of example 2 provided by the present invention was applied to the affected part, and the wound was healed after 2 days.
2. Liangjia, male, age 30. When the brick is built, fingers are scratched by the brick, the solid wound containing the antibacterial cleaning composition of the embodiment 2 is pasted on an affected part after the wound is cleaned, the pain is obviously relieved after 10 minutes, and the wound is healed after 2 days.
3. Zhangqi, male, 11 years old. The liquid wound patch containing the antibacterial cleansing composition of example 2 of the present invention was applied to the affected part after scratching the fingers while playing and cleaning the wound, and the wound was healed after 2 days.
4. Leaf some, male, 28 years old. When cutting fruits, fingers were cut carelessly, the wounds were washed first, and then the antibacterial cleansing composition containing example 2 of the present invention was applied to the affected parts, and after 3 days, the wounds were healed without infection.
5. Suzhong, female, 67 years old. When a mosquito is swatted, the elbow accidentally touches the edge of the stainless steel frame to scrape the skin, after the wound is cleaned, the liquid wound plaster containing the antibacterial cleaning composition of the embodiment 2 is applied to the affected part, the pain is obviously relieved after 15 minutes, and the wound is healed after 2 days.
In summary, the antibacterial cleaning composition for wounds provided by the embodiments of the present invention can effectively resist staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa, cluster a B type hemolytic streptococcus and candida albicans, and the preparation method is simple, so that the antibodies can effectively exist at the same time, and are synergistic and excellent in activity. The wound plaster comprising the antibacterial cleaning composition has the advantages of effectively sterilizing wounds, preventing secondary infection of the wounds and promoting wound healing.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. An antibacterial cleansing composition for wounds, which is characterized in that the active ingredient comprises a composite yolk antibody, and the composite yolk antibody is prepared by the following method:
mixing inactivated staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa, A cluster B type hemolytic streptococcus and candida albicans to obtain a strain mixture, dissolving the strain mixture to obtain a composite antigen, injecting the composite antigen onto a chicken body for immune enhancement, collecting eggs laid by the chicken with enhanced immunity, and separating and purifying the eggs.
2. The antibacterial cleaning composition as claimed in claim 1, wherein the strain mixture comprises, by mass, 14% -20% of staphylococcus aureus, 10% -15% of escherichia coli, 10% -20% of acinetobacter baumannii, 9% -15% of pseudomonas aeruginosa, 25% -40% of cluster a B type hemolytic streptococcus and 10% -15% of candida albicans.
3. The antibacterial cleaning composition as claimed in claim 2, wherein the strain mixture comprises, by mass, 15% -17% of staphylococcus aureus, 10% -13% of escherichia coli, 13% -17% of acinetobacter baumannii, 10% -12% of pseudomonas aeruginosa, 30% -40% of cluster a B type hemolytic streptococcus and 10% -11% of candida albicans.
4. The antimicrobial cleansing composition of claim 1 wherein the active ingredient further comprises guanidinated chitosan, dimethyl sulfoxide, ginseng oligopeptides, and vitamin E.
5. The antibacterial cleaning composition according to claim 4, wherein the mass ratio of the complex yolk antibody, the guanidinated chitosan, the dimethyl sulfoxide, the ginseng oligopeptide and the vitamin E is 1.3-2.5:0.3-0.5:0.3-0.5:1-2:0.05-0.1 in sequence.
6. The antimicrobial cleansing composition of claim 1 wherein the step of solubilizing said mixture of bacterial strains to produce a complex antigen comprises:
and mixing the dissolved strain mixture with a Freund's adjuvant according to a mass ratio of 1:1-1.3, and homogenizing, wherein the concentration of the strain mixture is 0.8-2.5 mg/ml.
7. A wound covering comprising an antibacterial cleansing composition according to any one of claims 1 to 6.
8. The wound covering of claim 7 which is a solid wound covering further comprising a strip of adhesive tape, a backing layer and a release paper, the backing layer being loaded with the antimicrobial cleansing composition, the strip of adhesive tape having air-permeable apertures.
9. The wound covering of claim 7, which is a liquid wound covering, further comprising a carrier, the antibacterial cleansing composition being mixed with the carrier to form a colloidal solution, and the mass ratio of the antibacterial cleansing composition to the carrier being 1-10: 75-90.
10. The wound covering of claim 9, characterized in that the carrier comprises, by weight, 2-3 parts of nitrocellulose, 1-2 parts of polyvinylpyrrolidone, 1-2 parts of glycerol, 3-5 parts of ethanol, 3-5 parts of sodium alginate and 80-90 parts of deionized water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810880264.9A CN110787293A (en) | 2018-08-03 | 2018-08-03 | Antibacterial cleaning composition for wound and wound plaster |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810880264.9A CN110787293A (en) | 2018-08-03 | 2018-08-03 | Antibacterial cleaning composition for wound and wound plaster |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110787293A true CN110787293A (en) | 2020-02-14 |
Family
ID=69425341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810880264.9A Pending CN110787293A (en) | 2018-08-03 | 2018-08-03 | Antibacterial cleaning composition for wound and wound plaster |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110787293A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010824A (en) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | A kind of special yolk immune globulin composite and its preparation |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101033264A (en) * | 2007-04-24 | 2007-09-12 | 武汉大学 | Chitosan biguanide hydrochloride, preparation method and use thereof |
| WO2011117384A1 (en) * | 2010-03-26 | 2011-09-29 | B. Braun Melsungen Ag | Antimicrobial wound dressing |
| CN102977208A (en) * | 2012-12-12 | 2013-03-20 | 大连医科大学 | Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit |
| CN104013958A (en) * | 2014-04-30 | 2014-09-03 | 广州汇高生物科技有限公司 | Specificity yelk immune globulin composition for preventing pathogenic bacteria and preparation thereof |
| CN104208741A (en) * | 2013-05-29 | 2014-12-17 | 陆建国 | Chitosan based adhesive bandage |
| CN105126150A (en) * | 2015-09-26 | 2015-12-09 | 谈伟强 | Adhesive bandage containing chitosan mixture and preparation method of adhesive bandage |
| CN108042839A (en) * | 2017-12-19 | 2018-05-18 | 湖北工程学院 | A kind of chitosan complexes bandage and preparation method thereof |
-
2018
- 2018-08-03 CN CN201810880264.9A patent/CN110787293A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101033264A (en) * | 2007-04-24 | 2007-09-12 | 武汉大学 | Chitosan biguanide hydrochloride, preparation method and use thereof |
| WO2011117384A1 (en) * | 2010-03-26 | 2011-09-29 | B. Braun Melsungen Ag | Antimicrobial wound dressing |
| CN102977208A (en) * | 2012-12-12 | 2013-03-20 | 大连医科大学 | Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit |
| CN104208741A (en) * | 2013-05-29 | 2014-12-17 | 陆建国 | Chitosan based adhesive bandage |
| CN104013958A (en) * | 2014-04-30 | 2014-09-03 | 广州汇高生物科技有限公司 | Specificity yelk immune globulin composition for preventing pathogenic bacteria and preparation thereof |
| CN105126150A (en) * | 2015-09-26 | 2015-12-09 | 谈伟强 | Adhesive bandage containing chitosan mixture and preparation method of adhesive bandage |
| CN108042839A (en) * | 2017-12-19 | 2018-05-18 | 湖北工程学院 | A kind of chitosan complexes bandage and preparation method thereof |
Non-Patent Citations (9)
| Title |
|---|
| 姚心培等: "胍基壳聚糖的止血性能和细胞毒性", 《中国组织工程研究》 * |
| 姚心培等: "胍基壳聚糖的止血性能和细胞毒性", 《中国组织工程研究》, no. 06, 28 February 2017 (2017-02-28), pages 291 - 292 * |
| 方媛等: "抗菌淀粉-聚乙烯醇水凝胶的制备及性能", 《功能高分子学报》 * |
| 方媛等: "抗菌淀粉-聚乙烯醇水凝胶的制备及性能", 《功能高分子学报》, no. 03, 15 September 2011 (2011-09-15) * |
| 梁丽媚等: "壳聚糖及其衍生物抗菌活性的研究进展", 《广州化工》 * |
| 梁丽媚等: "壳聚糖及其衍生物抗菌活性的研究进展", 《广州化工》, no. 20, 23 October 2017 (2017-10-23) * |
| 王建清 等: "《"十二五"普通高等教育本科国家级规划教材 包装材料学 第2版》", 28 February 2017 * |
| 金绍娣: "双胍基苯甲酰壳聚糖盐酸盐抗菌活性的研究", 《辽宁丝绸》 * |
| 金绍娣: "双胍基苯甲酰壳聚糖盐酸盐抗菌活性的研究", 《辽宁丝绸》, no. 03, 25 September 2012 (2012-09-25) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010824A (en) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | A kind of special yolk immune globulin composite and its preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102132543B1 (en) | Petrolatum-based composition comprising cationic biocide | |
| JP3981151B2 (en) | Composition for inactivating stimulants in a liquid | |
| WO2010079209A2 (en) | Compositions for treating wounds and skin conditions | |
| CN105012993A (en) | Medical and antibacterial cationic biogel dressing and preparation method thereof | |
| BRPI0716270A2 (en) | dry wound bandage and drug delivery system | |
| CA1238272A (en) | Method and composition for treating skin lesions | |
| CN105169455B (en) | A kind of burn and scald external application first aid medical dressing and preparation method thereof | |
| Doanh et al. | The use of a water extract from the bark of Choerospondias axillaris in the treatment of second decree burns | |
| CN110787293A (en) | Antibacterial cleaning composition for wound and wound plaster | |
| de Maquinarias et al. | The use of tannic acid in the local treatment of burn wounds: intriguing old and new perspectives | |
| RU2146136C1 (en) | Antiseptic "katapel" | |
| JP6690816B2 (en) | Disinfecting composition containing polyvinylpyrrolidone and unithiol and use of the composition | |
| US10285938B2 (en) | Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring | |
| CN109395068A (en) | A kind of refractory wound Special sterilizing liquid | |
| RU100724U1 (en) | ATRAUMATIC BANDING AGENT WITH NANOPARTICLES OF ASEPTICA SILVER | |
| CN114225100A (en) | Porphyridium-based liquid dressing and preparation method thereof | |
| WO2020232456A2 (en) | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity | |
| Moniruzzaman et al. | Pediatric First-Degree Burn Management With Honey and 1% Silver Sulfadiazine (Ag-SD): Comparison and Contrast | |
| US11565020B2 (en) | Powdered collagen wound care compositions | |
| RU2781402C2 (en) | Niosomal antimicrobial gel for treating diabetic ulcers, wounds, burns, including those infected with antibiotic-resistant microorganisms | |
| Khandelwal et al. | A comparative study of the effect on healing of ulcer using silver dressing | |
| RU2403014C1 (en) | Wound healing agent | |
| US20220168317A1 (en) | Therapeutic Thiazine Dye Compositions and Methods of Use | |
| Sang et al. | Research on nursing of common open trauma under nano antibacterial technology | |
| RU2192266C2 (en) | Method for preparing skin cover defect to autodermoplasty operation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200214 |